News
End of Unnecessary Biopsies? Prostate Health Index (PHI) in Detecting Aggressive Carcinoma
The Prostate Health Index (PHI) combines the results of three blood-derived parameters: total PSA (tPSA), free PSA (fPSA), and [-2]proPSA (p2PSA) into a single numerical score: PHI = (p2PSA / fPSA × √tPSA). It is a marker used to differentiate patients indicated for prostate biopsy, enabling prediction of cancer aggressiveness and helping to choose the optimal course of action for a particular patient. Its benefit in distinguishing aggressive prostate cancer from indolent tumors or benign lesions was already proven in 2015.
Prediction of Cancer Aggressiveness: Prostate Health Index (PHI) as a Promising Future Marker
The Prostate Health Index (PHI) is a diagnostic blood test that combines the levels of…
Cardiovascular Benefit of SGLT2 Inhibitors Confirmed
The cardiovascular (CV) benefit of SGLT2 inhibitors in type 2 diabetics, demonstrated by empagliflozin...
Why Do Women in the USA Receive Indicated Statin Therapy Less and in Lower Doses Than Men?
Statin use has been proven to reduce the risk of cardiovascular diseases in both men and women.…
Efficacy and Safety of High Doses of Enoxaparin in Preventing Thromboembolic Disease in Morbidly Obese Patients
Thromboembolic disease is a significant cause of morbidity and mortality in hospitalized patients,…
Prophylaxis of Thromboembolism with Low-Molecular-Weight Heparins in Oncology Patients: Efficacy and Safety of Doses Adjusted According to Anti-Xa Activity
Oncological patients undergoing surgical procedures are observed to have a high risk of…
Evaluation of the m7-FLIPI score in patients with follicular lymphoma revealed a promising predictive biomarker for determining suitable chemotherapy
The authors of a study presented at the December congress of the American Society of Hematology…
Kadcyla in a New Indication – Adjuvant Therapy for Early HER2+ Breast Cancer
In December, the European Commission approved the expansion of the indication for Roche's medicinal…
Comparison of Safety and Efficacy of Oral and Intravenous Administration of Combination NEPA in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting
Both oral and intravenous administration of a combination of netupitant (a neurokinin 1 receptor…
Cost Effectiveness of Netupitant/Palonosetron Combination in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting
A recently published study compared the costs of achieving a complete response to antiemetic…